Annual Total Expenses
$2.26 B
+$211.05 M+10.29%
31 December 2023
Summary:
BioMarin Pharmaceutical annual total expenses is currently $2.26 billion, with the most recent change of +$211.05 million (+10.29%) on 31 December 2023. During the last 3 years, it has risen by +$308.84 million (+15.82%). BMRN annual total expenses is now at all-time high.BMRN Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Expenses
$631.85 M
+$40.27 M+6.81%
30 September 2024
Summary:
BioMarin Pharmaceutical quarterly total expenses is currently $631.85 million, with the most recent change of +$40.27 million (+6.81%) on 30 September 2024. Over the past year, it has increased by +$76.09 million (+13.69%). BMRN quarterly total expenses is now -0.01% below its all-time high of $631.93 million, reached on 31 December 2023.BMRN Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Total Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +10.3% | +13.7% |
| 3 y3 years | +15.8% | +37.3% |
| 5 y5 years | +37.4% | +38.2% |
BMRN Total Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +17.7% | -0.0% | +37.3% |
| 5 y | 5 years | at high | +37.4% | -0.0% | +39.5% |
| alltime | all time | at high | >+9999.0% | -0.0% | >+9999.0% |
BioMarin Pharmaceutical Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $631.85 M(+6.8%) |
| June 2024 | - | $591.58 M(+3.7%) |
| Mar 2024 | - | $570.37 M(-9.7%) |
| Dec 2023 | $2.26 B(+10.3%) | $631.93 M(+13.7%) |
| Sept 2023 | - | $555.76 M(+4.9%) |
| June 2023 | - | $529.71 M(-0.8%) |
| Mar 2023 | - | $534.01 M(-4.9%) |
| Dec 2022 | $2.05 B(+6.7%) | $561.44 M(+10.8%) |
| Sept 2022 | - | $506.82 M(+2.6%) |
| June 2022 | - | $493.75 M(+1.2%) |
| Mar 2022 | - | $488.03 M(-5.1%) |
| Dec 2021 | $1.92 B(-1.6%) | $514.04 M(+11.7%) |
| Sept 2021 | - | $460.11 M(-5.7%) |
| June 2021 | - | $487.87 M(+6.4%) |
| Mar 2021 | - | $458.59 M(-7.1%) |
| Dec 2020 | $1.95 B(+7.9%) | $493.90 M(-7.0%) |
| Sept 2020 | - | $530.85 M(+12.8%) |
| June 2020 | - | $470.42 M(+3.0%) |
| Mar 2020 | - | $456.63 M(+0.8%) |
| Dec 2019 | $1.81 B(+9.9%) | $452.97 M(-0.9%) |
| Sept 2019 | - | $457.09 M(+2.9%) |
| June 2019 | - | $444.06 M(-2.3%) |
| Mar 2019 | - | $454.70 M(+12.9%) |
| Dec 2018 | $1.65 B(+13.3%) | $402.92 M(-1.1%) |
| Sept 2018 | - | $407.45 M(-2.5%) |
| June 2018 | - | $418.11 M(+0.1%) |
| Mar 2018 | - | $417.82 M(-1.7%) |
| Dec 2017 | $1.45 B(+10.0%) | $425.26 M(+22.2%) |
| Sept 2017 | - | $347.88 M(-2.4%) |
| June 2017 | - | $356.26 M(+10.0%) |
| Mar 2017 | - | $323.95 M(-16.9%) |
| Dec 2016 | $1.32 B(+12.8%) | $389.71 M(+14.6%) |
| Sept 2016 | - | $339.98 M(+24.2%) |
| June 2016 | - | $273.82 M(-13.8%) |
| Mar 2016 | - | $317.65 M(+6.8%) |
| Dec 2015 | $1.17 B(+28.8%) | $297.42 M(+2.3%) |
| Sept 2015 | - | $290.78 M(-7.5%) |
| June 2015 | - | $314.42 M(+17.0%) |
| Mar 2015 | - | $268.78 M(-6.9%) |
| Dec 2014 | $909.67 M(+29.3%) | $288.82 M(+24.0%) |
| Sept 2014 | - | $232.85 M(+10.5%) |
| June 2014 | - | $210.67 M(+18.3%) |
| Mar 2014 | - | $178.01 M(-10.2%) |
| Dec 2013 | $703.55 M(+15.2%) | $198.24 M(+5.7%) |
| Sept 2013 | - | $187.60 M(+19.6%) |
| June 2013 | - | $156.86 M(-2.5%) |
| Mar 2013 | - | $160.85 M(-10.1%) |
| Dec 2012 | $610.94 M(+28.6%) | $178.84 M(+29.0%) |
| Sept 2012 | - | $138.61 M(-10.6%) |
| June 2012 | - | $154.97 M(+11.9%) |
| Mar 2012 | - | $138.51 M(+7.1%) |
| Dec 2011 | $475.25 M | $129.28 M(+0.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2011 | - | $128.94 M(+13.9%) |
| June 2011 | - | $113.19 M(+5.9%) |
| Mar 2011 | - | $106.85 M(-3.9%) |
| Dec 2010 | $375.72 M(+21.9%) | $111.17 M(+16.1%) |
| Sept 2010 | - | $95.72 M(+9.6%) |
| June 2010 | - | $87.33 M(+6.3%) |
| Mar 2010 | - | $82.16 M(+1.8%) |
| Dec 2009 | $308.23 M(+20.1%) | $80.70 M(+14.2%) |
| Sept 2009 | - | $70.67 M(-9.9%) |
| June 2009 | - | $78.47 M(+0.1%) |
| Mar 2009 | - | $78.38 M(+16.6%) |
| Dec 2008 | $256.74 M(+43.5%) | $67.22 M(-4.4%) |
| Sept 2008 | - | $70.30 M(+17.9%) |
| June 2008 | - | $59.64 M(+0.1%) |
| Mar 2008 | - | $59.58 M(+8.7%) |
| Dec 2007 | $178.87 M(+64.3%) | $54.80 M(+29.5%) |
| Sept 2007 | - | $42.31 M(-0.4%) |
| June 2007 | - | $42.48 M(+7.2%) |
| Mar 2007 | - | $39.63 M(+18.0%) |
| Dec 2006 | $108.88 M(+21.1%) | $33.58 M(+15.6%) |
| Sept 2006 | - | $29.04 M(+17.2%) |
| June 2006 | - | $24.79 M(+15.4%) |
| Mar 2006 | - | $21.47 M(-3.7%) |
| Dec 2005 | $89.88 M(-46.0%) | $22.30 M(+7.5%) |
| Sept 2005 | - | $20.75 M(-7.4%) |
| June 2005 | - | $22.40 M(-8.3%) |
| Mar 2005 | - | $24.43 M(-74.9%) |
| Dec 2004 | $166.55 M(+89.5%) | $97.45 M(+263.6%) |
| Sept 2004 | - | $26.80 M(+16.7%) |
| June 2004 | - | $22.96 M(+18.8%) |
| Mar 2004 | - | $19.34 M(-23.0%) |
| Dec 2003 | $87.90 M(+30.0%) | $25.11 M(+21.5%) |
| Sept 2003 | - | $20.67 M(-4.2%) |
| June 2003 | - | $21.58 M(+5.0%) |
| Mar 2003 | - | $20.54 M(+32.8%) |
| Dec 2002 | $67.62 M(+42.0%) | $15.47 M(-16.9%) |
| Sept 2002 | - | $18.61 M(+13.5%) |
| June 2002 | - | $16.40 M(-4.4%) |
| Mar 2002 | - | $17.14 M(+130.8%) |
| Dec 2001 | $47.63 M(+4.9%) | $7.43 M(-44.6%) |
| Sept 2001 | - | $13.42 M(+2.9%) |
| June 2001 | - | $13.04 M(+17.2%) |
| Mar 2001 | - | $11.13 M(-15.8%) |
| Dec 2000 | $45.39 M(+46.0%) | $13.22 M(+19.6%) |
| Sept 2000 | - | $11.05 M(+7.6%) |
| June 2000 | - | $10.27 M(-5.2%) |
| Mar 2000 | - | $10.84 M(+35.5%) |
| Dec 1999 | $31.10 M(+120.6%) | $8.00 M(-18.4%) |
| Sept 1999 | - | $9.80 M(+27.3%) |
| June 1999 | - | $7.70 M(+35.4%) |
| Mar 1999 | - | $5.69 M |
| Dec 1998 | $14.10 M | - |
FAQ
- What is BioMarin Pharmaceutical annual total expenses?
- What is the all time high annual total expenses for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual total expenses year-on-year change?
- What is BioMarin Pharmaceutical quarterly total expenses?
- What is the all time high quarterly total expenses for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly total expenses year-on-year change?
What is BioMarin Pharmaceutical annual total expenses?
The current annual total expenses of BMRN is $2.26 B
What is the all time high annual total expenses for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual total expenses is $2.26 B
What is BioMarin Pharmaceutical annual total expenses year-on-year change?
Over the past year, BMRN annual total expenses has changed by +$211.05 M (+10.29%)
What is BioMarin Pharmaceutical quarterly total expenses?
The current quarterly total expenses of BMRN is $631.85 M
What is the all time high quarterly total expenses for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly total expenses is $631.93 M
What is BioMarin Pharmaceutical quarterly total expenses year-on-year change?
Over the past year, BMRN quarterly total expenses has changed by +$76.09 M (+13.69%)